ROCKVILLE, Md.--(BUSINESS WIRE)--Supernus Pharmaceuticals, Inc. today announced that it closed a private placement to institutional investors of $75 million in aggregate principal amount of non-convertible, non-recourse promissory notes. The notes are secured by royalties generated from sales of Oracea® and Sanctura® XR, two products that use Supernus technologies and are marketed by its licensees and/or sub-licensees.
